ScholarLens Back to search
2010•Current Opinion in OphthalmologyRequires access

Pharmacologic treatment of atrophic age-related macular degeneration

Nathan L. Mata, Roger Vogel

Open publisher page 26 citations

Abstract

PURPOSE OF REVIEW: To review and compare the various therapeutic platforms, investigational drugs, and clinical trials targeting geographic atrophy in age-related macular degeneration. RECENT FINDINGS: Investigational agents based on hypothesized causes are being developed to treat geographic atrophy. These platforms are designed to attack the disease on several different fronts. SUMMARY: As knowledge of geographic atrophy pathophysiology advances, targeted pharmacotherapies may well be able to mitigate the retinal damage and vision loss associated with geographic atrophy.

About this research paper

What this paper is about

PURPOSE OF REVIEW: To review and compare the various therapeutic platforms, investigational drugs, and clinical trials targeting geographic atrophy in age-related macular degeneration. RECENT FINDINGS: Investigational agents based on hypothesized causes are being developed to treat geographic atrophy. These platforms are designed to attack the disease on several different fronts. SUMMARY: As knowledge of geographic atrophy pathophysiology advances, targeted pharmacotherapies may well be able to mitigate the retinal damage and vision loss associated with geographic atrophy.

Why it matters

OpenAlex reports 26 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

PURPOSE OF REVIEW: To review and compare the various therapeutic platforms, investigational drugs, and clinical trials targeting geographic atrophy in age-related macular degeneration. RECENT FINDINGS: Investigational agents based on hypothesized causes are being developed to treat geographic atrophy. These platforms are designed to attack the disease on several different fronts. SUMMARY: As knowledge of geographic atrophy pathophysiology advances, targeted pharmacotherapies may well be able to mitigate the retinal damage and vision loss associated with geographic atrophy.

Key concepts: Medicine, Macular degeneration, Ophthalmology, Degeneration (medical), Dermatology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Pharmacologic treatment of atrophic age-related macular degeneration — Research Paper | ScholarLens